Cargando…

The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis

Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenneck, Claudia, Novak, Natalija
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/
https://www.ncbi.nlm.nih.gov/pubmed/18488075